Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
LHGDN |
HER3 expression correlated with the presence of lymph node metastasis, tumor type, and higher N stage; the expression of HER4 correlated with lower T stage.
|
18424286 |
2008 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
HER-3 is closely related to tumorigenesis, progression and metastasis.
|
24084886 |
2013 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
HER3 overexpression was inversely correlated with histologic grade (p = 0.006), tumour size (p < 0.001), tumour depth (p < 0.001), TNM stage (p = 0.002), lymphatic invasion (p = 0.004), lymph node metastasis (p = 0.013) and distant metastasis (p = 0.039).
|
25739551 |
2015 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
A slight increase (35-40%) in CK19 and HER3 expression was observed in the tumors of patients with SLN metastases compared to those of patients without metastases, even if neither CK19 expression nor HER3 expression allowed to distinguish patients with micrometastases from patients with macrometastases.
|
18409145 |
2008 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Aberrant regulation of the EGF receptor family (EGFR, HER2, HER3, HER4) contributes to tumorigenesis and metastasis in epithelial cancers.
|
26420857 |
2016 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Abnormal HER2 activation, either through HER2 overexpression or heregulin (HRG):HER3 binding, elicits the formation of potent HER2-HER3 heterodimers and drives breast cancer cell growth and metastasis.
|
23378579 |
2013 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Collectively these data suggest mechanisms by which the HER3-HER2 dimer promotes development of metastatic tumors in the heregulin-rich brain microenvironment.
|
25668816 |
2015 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Epidermal growth factor receptor family members such as ErbB1 and ErbB3 are involved in tumor progression and metastasis.
|
30621788 |
2019 |
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Furthermore, increased ROR1, p-HER3 Tyr1307 and MAYA levels correlate with tumour metastasis and unfavourable outcomes.
|
28114269 |
2017 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, the carriers of T genotype was related to the significantly high expression of ErbB3, and to big tumor size, poor differentiation as well as the high probability of metastasis.
|
28924391 |
2017 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
High HER-3 expression was significantly associated with an advanced Enneking stage and distant metastasis.
|
30008917 |
2018 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
However, a functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on tumor metastasis has not been conducted.
|
22627808 |
2012 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Immunohistochemical expression of EGFR, HER2 and HER3 was examined and compared in pretreatment biopsies, post-treatment surgical resection specimens and metastases in a retrospective cohort of 166 patients with adenocarcinoma of the oesophagus or stomach.
|
29138285 |
2018 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, EGFR and HER3 expression in metastasized NSCLC patients have considerable value for CTC isolation plus multiple markers can provide a novel liquid biopsy approach.
|
31092882 |
2019 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, quantification of EGFR and HER3 mRNA expression in pretreatment biopsies may be useful to identify patients who are at risk of developing metastases.
|
20824716 |
2011 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
In nude mice, the expression of c-erbB-3 mRNA was higher in metastatic tumors compared with primary tumors.
|
9499191 |
1998 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Lnc-ing ROR1-HER3 and Hippo signalling in metastasis.
|
28139652 |
2017 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Moreover, ECM1-induced galectin-3 cleavage through upregulation of matrix metalloproteinase 9 not only improved mucin 1 expression, but also increased EGFR and human epidermal growth factor receptor 3 protein stability as a secondary signaling.
|
25499743 |
2014 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Our data provide insights into the mechanistic regulation and linkage of the ROR1-HER3 and Hippo-YAP pathway in a cancer-specific context, and also imply valuable therapeutic targets for bone metastasis and possible therapy-resistant tumours.
|
28114269 |
2017 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of HER3 following targeted therapy can occur rapidly and heterogeneously both within a single lesion and across sites of metastasis, making protein quantification by biopsy highly challenging.
|
28733706 |
2018 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
SIGNIFICANCE: These findings uncover a unique interplay between AXL and ERBB3 in invadopodia regulation that points to the need for combined therapy in order to prevent invadopodia-mediated metastasis in melanoma.
|
30914429 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Strong HER3 staining was found in 26.7% of both the primary tumors and the corresponding metastases.
|
18172732 |
2008 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
LHGDN |
The HER3 staining (weak or strong) was mainly cytoplasmic and granular and was observed in about half (20/39) of the cases, for both the ESCC primary tumours and the corresponding lymph node metastases.
|
17671674 |
2007 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The authors conclude that downregulation of KRT19 is highly associated with tumor progression in NB and metastasis in localized primary NB and that low expression of ERBB3 is also associated with progression of NB.
|
23135478 |
2013 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The hazard risk for metastasis development in stage I/II disease was increased at least 3-fold for tumors with high expression levels of insulin receptor, neurotrophic tyrosine receptor kinase 1, epidermal growth factor receptor, ERBB2, ERBB3, platelet-derived growth factor receptor beta, fibroblast growth factor receptor 1, or leukocyte tyrosine kinase.
|
15753374 |
2005 |